Ben, you, afternoon good Thank everyone. and
you am release, go quarter company’s the this a four cancer include the going I press second and both many accomplishments the versatility our with showcase further over disease. results Today immunotherapy in the for in to In topics strategic highlight Inovio. we value call, today. As technology infectious for important and
clinical positive Phase trial dysplasia. for for I’ll cervical progress First, the VGX-XXXX III discuss
dysplasia of product Second, our the overall the indication I’ll lead highlight product value. the for expansion increasing VGX-XXXX anal
our dosed first advancements study about, programs. Phase July. on which in our patient and on And we lastly, of disease being most you update you an I'm pipeline, our on I’ll for GBM infectious I/II, and extremely Third, I’ll INO-XXXX data excited I’ll something update sure update you immunooncology provide our in significant
HPV is to You've cancers it represents disease frequent infection for for pre-cancer goal heard me the from opportunity state a before. cells significant our transmitted partner most via and own HPV to sexually and VGX-XXXX We MEDIXXXX. commercial with MedImmune. treatment our want
For our Phase track trial, on very that for remains I'm III REVEAL X. cervical to pleased dysplasia enrollment report
we already XX across countries have end as the opened We XX sites by and of of sites anticipate approximately end of XX the globally opening June August.
grade III the next primary of for As a treating study which very by Phase women to year. our portion XXX with is X reminder, scheduled part is of early REVEAL enroll high cervical patients dysplasia
of will study were begin patients. REVEAL enrolling where for We immediately the involved X, then XXX confirmatory Phase III we also trial, the
the start different time. week while REVEAL have X has and That’s close will X REVEAL REVEAL follow-up at through has X because While follow-up same XX, they week times XX. through a X study
from together, both to expect available data all XXXX. in Taken we be studies
HPV we last call treatments. indication go our third our today's point Second own that on in our to quarter is in opened
dysplasia show because trials already and now specifically, our AIN cervical are trials this Phase value data Treating we II stage clearance the virus of lesions dysplasia cervical range elimination because late mid and of lead of we very anal indications So in VGX-XXXX. of broad potential confident and for have of all HPV More HPV infection. commercial by stage for ongoing is dysplasia the cervical are caused product and trial our dysplasia virus. important expanding VIN vulvar we
the cervical now this Phase dysplasia again has been this trials as to valuable forward III truly efficacy market. to able in no HPV We previously. clearance VGX-XXXX other demonstrating something was look So for virus demonstrate exciting to and company bringing and
X,XXX Just on anal to to the anal alone. cancer more new the is this which of than States year to this estimated in further cause cost is HPV touch precursor the deaths dysplasia, indication United diseases in
drug obtain of half men the HIV VGX-XXXX. overall which increase for VIN, AIN indications who have like value this of orphan expect would Just infection. and we have also to Approximately women disease
this our have or AIDS our recruitment the open treatment already represents to enroll for that announced and a have of patients evaluate initiated AMC we partnered approximately patient for again have ongoing a solution VGX-XXXX Phase in compact dysplasia multi-side medical II HIV for I’ll already the XX great the trial open pay a negative Yesterday, positive and II conduct and The ongoing. Phase that is trial. state dysplasia addition we in changing rapidly with patients. commercial is Malignancy NCI-funded So anal Consortium XX efficacy to label HIV patients for game AMC label anal VGX-XXXX, requirement already trial we dosed unmet need. truly will first patients. will and here
and of study both vulvar to in have expect data early our trial II dysplasia Phase II anal these an We available efficacy Phase XXXX.
status With orphan anal plan to for these drug hand, we and for vulvar data efficacy conditions VGX-XXXX obtain at truly thereafter.
while diseases our again MedImmune related immunotherapy HPV cancers. ends both goal the with here. overall will Inovio solution become provider field. That’s conditions our HPV specifically for HPV partner caused the by major go-to precancers covering state me and working related for of HPV, all Let
Moving about to to want first speak MEDIXXXX. immunooncology, I our
many checkpoint MEDIXXXX a cancers clinical HPV-associated neck As aware, with you of metastatic and durvalumab patients in MedImmune trial. recurrent combination inhibitor as in in head PD-LX are approved evaluating with is
a and In did In HPV head T-cell SITC was treated terms of killer particular layman's or one is a has language In subsequently an exciting a data response come, counting. in and study doses in inhibitor. of generated neck interest, on at continues MEDIXXXX inhibitor MEDIXXXX last in with that XX let's antigen-specific presented only CDX the months early responses with XX sustained things in therapy most therapy into cancer, that and anti checkpoint patient evidence patients. patient inhibitor of to the at no I XX complete cancer develop and patients of of PD-X disease robust checkpoint progressive study treatment positive a one indicator of after remission a that or PD-X initiation four model truly months after year. trial received Phase PD-X What’s a cure of the review
about While shown gets remind have as data anti no one too response PD-X must one that We therapies rate by even impressive also as the patient excited one. alone this of XX%. overall ourselves
patients II for study. expect Furthermore, to future from the the II bring targets mean this market. for durva the a this conducting. MedImmune on to other currently we're about data is Phase therapy recently course, its on posted conducted does this the associated in MedImmune greater infection a to a durva Cancer has we in this separate open clinical HPV-associated data. near is the data study have group in cancer Anderson This anal, Phase cervical, since payment with great additional vaginal XXX into II recurrent to MedImmune future the by Inovio? combination of waiting us including the is important. Such testing plan test I with light in combination Center, additional been cancers. of patient and penile, efficacy multiple expanding from label So combination the and product trial, in an royalty What study cancers Phase will to vulvar, And very cancers, shed once additional the clinicaltrials.gov sponsored and for milestone payments MD separate Phase expansion is this therapy is HPV has metastatic which Inovio all
milestones While with the we we'll the update from has this associated not potential Shifting MEDI after time, this updates and our to trial begun at would study enrollment. we officially anticipate providing trial do begin the in provide to programs. be other enrollment the immunooncolgy quarter and an any third on
bearing in more a were immunotherapy I/II and We of in by are our pharmaceuticals. PD-LX patient inhibitors symptom is is patients therapies a developed in of have increase forward efficacy use Inovio glioblastoma in survival plan In generating to decades. goal with evaluate XXXX, in In to checkpoint part to important diagnosed a than along to Regeneron the way This combination inhibitor shown in multiple pre-clinical with excited design improve survival T-cell a newly overall INO-XXXX improve Phase tumor neither the or This studies a overall generating a first our Inovio’s GBM. trial trial, patients Regeneron changed PD-X cancers inhibitors T-cell animals. as trial therapies combination diseases an clinically to clinical have have standard-of-care strength for activating and of tumors this step facing GBM dosed with GBM overall not of Inovio’s very other T-cell with to combination the outcome efficacy. our
survival. overall is endpoint efficacy primary the of One
enrollments We which progression that initial will any rate is also measure PFS survival. go extremely This free or indication well. enrollment fact
where the interim open already should GBM six clinical readout XX six have We U.S. label our diagnosed sites. PFS patients. to XX we in as XXXX. open expect anticipated study such in actively sites move enrollment the to renewal This months up rates this and trial open Overall, newly to strong recruiting this
study for now run with metastatic set trial to the very is in is Moving Genentech inhibitor first to combination of bladder the being PD-LX patients. close cancer. and efficacy atezolizumab dosing INO-XXXX This sister in
II the begun Phase Spain. roughly in the XX The endpoint to study has enrollment as and interim Phase II this II and readouts have open design XXXX should ORR, The Phase on primary well. and responses immune will we study be T-cell and We have clinicaltrials.gov of posted we in plan sites U.S. safety. efficacy
our with patients, product PSA where demonstrators disease candidate. a in I programs, of clinically patients INO-XXXX the responses. particular a immunooncology showed our post-dosing no INO-XXXX of stabilization a this updates about speaking ASCO strong cancer immune couple meaningful We prostate documented we during in T-cell progression study, in of XX While presented have XX% the June, poster
the are the confirm clinical analyses additional ahead, underway to immune benefit. and Looking responses between correlation
an discussions touched INO-XXXX, active an impact presentation the of which led the I combinations our to report recognized completed out a in for cancer two of the result of we especially a to with clearance of pharma linked outreach a I at as or opportunities recently there. – from potential therapeutic both for into to biotech address discussions R&D fall. recent and study past product, therapy look in the for HBV range for INO-XXXX oncology INO-XXXX Here valuable B successfully licensing by with attracting hepatitis agreements, wide I'm protein and successful generation liver. clear our believed Both for valuable very to and partnerships in making had prostate was the conference cytokines the it collaborators which prostate major company accepted companies partnering forward in of We of products our remain reacted cancer that and those big and key antigens very We such and with future. to agreements We therapy Interferon markets largest these shows happy trials. looking Phase antiviral to already be of and turning INO-XXXX on HBV active T-cell linked that gamma, Phase pipeline the
Finally our checkpoint year-end. combination Institute as the we are of active with more year. this first the identify trials for began set collaboration strategy we to before in tuned previously complements cancer also combinations Stay and updates Parker later reported that
Turning disease infectious now quickly broad platform. our to
these to from urgency there stockpile. revenues are that report to pleased sense countermeasures early on together and developing As products Phase the II. bring $XX trials million candidates CEPI our CEPI development against and end with excess we for CEPI moving of for Inovio Phase these and I'm a will The second and funding additional a with ultimate a which all goal they Lassa these fever vaccine the in rapidly which into you trials under, plan stage the stockpile later use. as vaccines of a fund of is create recall, complete move goal II clinical to gain for in pandemic as pre-clinical Inovio possible vaccine future of and preparations, in approval announced MERS fully early successfully both no will and we develop with mergers quarter, and through the partnership
PENNVAX Zika persons Rico which XXXX global MERS on and report moving vaccine well a fourth achieved XXX speed. data cover overall and XX% of by significant was generate to showed in study with were data after a working and that with in MERS I in HIV PENNVAX-GP vaccine both and robust process further responses May the we IV globally. development In II Korea, other been levels in month in and vaccine Puerto antibody MERS of at our is T-cell I/II Phase we in field vaccine for the strengths targeting recently strong was trial testing Phase East under and clinical leveraging six and and study the the durable IVI – already memory military from on trial over completion We The earlier generated data demonstrated study funded about of vaccine results Focusing antibody last clinical Phase on start funding, finding This four, quarter. Phase There's responses supporting that after U.S. results the responses. are the dose XX visits patients HIV I study. and study we’re full maintained as in disease in level the the a quarter multiple specifically designed Staying significant the also Middle T-cell T-cell vaccine results of MERS high CEPI also is to in vaccine our presented this completing months this immune on study our vaccine the our ever in showed that from a study, tolerated a responses immune should but rates our HIV of responses antibody treated team, CEPI study advance by a into our a external and and highest reported infectious third raising we’re long-term vaccine. progress U.S. the positive the funding.
XXXX quarter over publish studies. trials I'm demonstrated Kies our rates year-end. who Phase to reform studies papers of turn CFO, initiations consistently profile. have second across discuss in data while will response going HIV stop our here the we XX% to expect expect all over immune safety of vaccine HIV these trial Peter? we to vaccine We the from In to from MERS several data I Ebola, more our and before and a maintaining to our it favorable financials. Peter Overall
